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Abstract: Febuxostat is a novel, potent, non-purine selective xanthine oxidase inhibitor, 
which in clinical trials demonstrated superior ability to lower and maintain serum urate levels 
below 6 mg/dL compared with conventionally used doses of allopurinol. Febuxostat was well 
tolerated in long term treatment in patients with hyperuricemia including those experiencing 
hypersensitity/intolerance to allopurinol. Dose adjustment appears unnecessary in patients 
with mild to moderate renal or liver insufﬁ  ciency or advanced age. The most common adverse 
reactions reported were abnormal liver function tests, headache, and gastrointestinal symptoms, 
which were usually mild and transient. However, whether hepatotoxicity becomes a limitation in 
the use of febuxostat needs to be determined in further studies. An increased frequency of gout 
ﬂ  ares occurs for a prolonged period after treatment initiation, as with any aggressive lowering 
of serum urate, and prolonged prophylaxis with colchicine or NSAIDs is usually required. 
Febuxostat has been granted marketing authorization by the European Commission in early 
2008 for the treatment of chronic hyperuricemia and gout. Febuxostat is the ﬁ  rst major treat-
ment alternative for gout in more than 40 years and is a promising alternative to allopurinol, 
although continued long-term surveillance on safety and efﬁ  cacy is required.
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Introduction
Gout occurs as an acute arthritis that appears when there is a sudden onset of inﬂ  am-
mation in response to the accumulation of crystals of monosodium urate in or around 
a joint (Schlesinger 2004), which is closely associated with hyperuricemia. With 
persistent urate crystal deposition, gout may progress from acute episodic attacks to 
a disabling chronic deforming arthropathy, with destructive deposits of urate crystals 
(tophi) in bones, joints, subcutaneous tissue, and other organs (Becker 1988; Becker 
et al 2005b; Tomlinson 2005). Renal damage may occur due to interstitial urate crystal 
deposition and urinary tract stones composed entirely or partly of monosodium urate 
and uric acid crystals (Becker 1988; Schlesinger 2004).
The development of gout can be divided into four stages: asymptomatic 
hyperuricemia, the gouty attack, the intercritical period, and chronic gouty arthritis. 
It has been recognized that hyperuricemia may exist for many years before the ﬁ  rst 
clinical attack of gout (Falasca 2006). Hyperuricemia has been thought to be the 
fundamental pathogenic biochemical aberration upon which various etiological 
factors predispose to the expression of the clinical disorder of gout (Teng et al 2006). 
Moreover, hyperuricemia is also associated with chronic renal damage (Iseki et al 
2004), some metabolic disturbances and risk factors for atherosclerotic cardiovascular 
disease including hypertension, overweight, insulin resistance, and hyperlipidemia (Slot 
1994), which may occur together as the metabolic syndrome. This may explain the 
recognized association between gout and cardiovascular disease (Abbott et al 1988; 
Krishnan et al 2006; Choi and Curhan 2007), although there are no studies to show Therapeutics and Clinical Risk Management 2008:4(6) 1210
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whether lowering plasma urate will reduce the cardiovascular 
risk in humans (Kim et al 2003; Wortmann 2005).
Multiple epidemiological studies from a diverse range 
of countries suggest that gout has increased in prevalence 
and incidence in the past few decades and the proﬁ  le of 
clinical gout is becoming more complex (Roddy et al 2007). 
The established risk factors for gout include genetic factors, 
excess alcohol consumption, purine-rich diet, metabolic 
syndrome, use of diuretics, and chronic renal failure (Roddy 
et al 2007). Trends in lifestyle and dietary factors may partly 
explain the changes in the epidemiology of gout (Hak and 
Choi 2008). Furthermore, suboptimal management also 
contributes to the rising prevalence of clinically symptomatic 
chronic gout (Roddy et al 2007).
Conventional dietary recommendations for gout have 
emphasized the restriction of purine intake. There are two 
main approaches: the traditional low purine, low protein, 
alcohol-restricted diet, and more recently, a weight-reducing, 
purine-unlimited, calorie- and carbohydrate-restricted diet, 
with increased proportional intake of both protein and 
unsaturated fats. However, a rigid purine restricted diet is 
of dubious therapeutic value and there are also no long-term 
studies of the efﬁ  cacy of either approach (Fam 2002).
The treatment for an acute attack of gout is usually 
either colchicine or nonsteroidal anti-inﬂ  ammatory drugs 
(NSAIDs). For chronic gout, prophylactic therapy to 
reduce the serum urate level is thought to be appropriate 
in patients who have more than two gout ﬂ  ares a year or in 
individuals with gouty complications, and this could reduce 
the likelihood of recurrent gout by 80% (Emmerson 1996; 
Choi et al 2005; Bruce 2006). The physiochemical proper-
ties of monosodium urate cause crystals to precipitate in 
body ﬂ  uids if the concentration is greater than 6.8 mg/dL 
(400 μmol/L). Hence the target of urate lowering therapy 
is to reduce the serum urate concentration to below 
6.0 mg/dL (353 μmol/L), which should prevent the recur-
rence of gouty attacks or at least reduce their frequency 
substantially and allow the remission in size of gouty tophi 
(Wortmann 2005).
It was previously considered that it may be useful to 
divide subjects with hyperuricemia into those who are 
urate overproducers from those who are underexcreters, 
based on the 24-hour uric acid excretion (Wortmann 2002). 
Underexcreters may be candidates for uricosuric drugs 
such as probenecid or benzbromarone, but probenecid has 
limited efﬁ  cacy and/or safety in patients with renal impair-
ment or prior urolithiasis, and the more potent uricosuric 
agent benzbromarone was associated with several cases 
of fulminant hepatic failure and is not generally available 
(Emmerson 1996; Li-Yu et al 2001; Becker et al 2005b).
The urate-lowering therapy allopurinol, a xanthine 
oxidase (XO) inhibitor, has been the mainstay of prophylactic 
treatment for gout and conditions associated with hyperuri-
cemia for many years (Wortmann 2002). It is the treatment 
of choice for urate overproducers, tophaceous gout, neph-
rolithiasis, or urate nephropathy, and in patients with renal 
insufﬁ  ciency (Teng et al 2006). In theory allopurinol should 
be effective in almost every patient with hyperuricemia 
if a sufﬁ  cient dose is taken, but achieving normal serum 
urate levels may be difﬁ  cult in patients with impaired renal 
function or in transplant recipients (Schlesinger 2004). 
In practice approximately 20% of patients report side effects 
with allopurinol and 5% discontinue medication (Wortmann 
2005). There is a rare but serious hypersensitivity reaction to 
allopurinol, which involves fever, rash, eosinophilia, hepa-
titis, and progressive renal insufﬁ  ciency (Schlesinger 2004; 
Wortmann 2005). This appears to be dose- or plasma concen-
tration-dependent and can cause up to 20% mortality (Teng 
et al 2006). Patients with renal insufﬁ  ciency or receiving 
diuretic therapy are at increased risk of adverse effects 
(Wortmann 2005). It has been found that severe cutaneous 
adverse reactions, which include the drug hypersensitivity 
syndrome, Stevens-Johnson syndrome, and toxic epidermal 
necrolysis are strongly associated with the HLA-B*5801 
allele in Han Chinese patients, which could be developed 
as a screening test to identify the risk before commencing 
therapy (Hung et al 2005). As a result of frequent failure to 
reach target serum urate levels, or the intolerance to allo-
purinol in some patients, the development of an alternative 
potent serum urate lowering treatment has been a desirable 
goal. Febuxostat is a novel potent selective inhibitor of XO 
that appears to be well tolerated in all groups of patients, 
including those who are sensitive to allopurinol.
Pharmacology
Febuxostat, {TEI-6720, TMX-67, 2-[3-cyano-4-(2-methyl-
propoxy) phenyl]-4-methyl- thiazole-5-carboxylic acid}, is 
a non-purine compound with the empiric chemical formula 
C16H16N2O3S and molecular weight of 316.38 (Bruce 2006). 
It is a selective inhibitor of XO that has been developed for the 
treatment of hyperuricemia and gout, as it was found to have 
a potent inhibitory activity for XO/xanthine dehydrogenase 
(XDH) during evaluation of a range of newly synthesized 
molecules (Komoriya et al 1993). In humans, the xanthine 
oxidoreductase (XOR) enzyme catalyzes the last two steps in 
uric acid synthesis, the oxidation of hypoxanthine to xanthine Therapeutics and Clinical Risk Management 2008:4(6) 1211
Febuxostat for the treatment of hyperuricemia
and of xanthine to uric acid (hypoxanthine → xanthine → uric 
acid). Humans and the great apes lack the enzyme uricase 
which converts uric acid into allantoin (Osada et al 1993). 
Some non-enzymatic conversion of uric acid to allantoin does 
take place and the ratio of serum urate to allantoin has been 
considered as a potential marker of oxidative stress (Benzie 
et al 1999).
XOR is synthesized as XDH, which in mammals can 
easily be converted to XO by oxidation of sulfhydryl resi-
dues or by proteolysis (Okamoto et al 2003). Febuxostat was 
shown to inhibit both the oxidized and reduced forms of  XO, 
unlike allopurinol and oxypurinol, each of which binds only 
to one form of the enzyme (Okamoto et al 2003; Takano et al 
2005). The molecular mechanism of inhibition of  XO activity 
by febuxostat (Adenuric®, Ipsen, Paris, France) is by high 
afﬁ  nity binding to the enzyme in a molecular channel leading 
to the molybdenum-pterin active site, whereas allopurinol 
exerts relatively weak competitive inhibition on activity of 
only the oxidized form of XO (Okamoto et al 2003; Takano 
et al 2005). In contrast to allopurinol and oxypurinol, febuxo-
stat does not structurally resemble purines or pyrimidines and 
has no signiﬁ  cant effect on the activities of other enzymes 
involved in purine and pyrimindine metabolism, which might 
relate to some of the adverse effects caused by allopurinol 
and its metabolites (Takano et al 2005).
More recently, Okamoto and Nishino have reported 
that XOR inhibitors can be categorized into different types 
according to the crystal structure of the various inhibitors 
binding to XOR (Okamoto and Nishino 2008). Febuxostat 
has numerous hydrogen bonds, salt bridges, and hydro-
phobic interactions with amino acids in the active site and 
almost completely ﬁ  lls the narrow channel leading to the 
molybdenum center of the enzyme, which is considered 
as a structure-based inhibitor, whereas allopurinol and 
oxypurinol are thought to be mechanism-based inhibitors 
(Okamoto and Nishino 2008). The XO inhibitory activity and 
hypouricemic effect of febuxostat compared to allopurinol 
have been studied in vitro and in a variety of animal models 
(Komoriya et al 1993; Osada et al 1993; Horiuchi et al 1999). 
All these studies demonstrated that febuxostat had a greater 
potency than allopurinol in reducing serum urate levels 
and/or allantoin levels. Furthermore, the pleiotropic effects 
of febuxostat dependent on its hypouricemic effect have also 
been investigated and these studies provided a foundation 
for later evaluations in humans (Sanchez-Lozada et al 2008a, 
b, c; Zhao et al 2008).
As increased fructose consumption is associated with 
hyperuricemia, the metabolic syndrome, and renal damage, 
Sanchez-Lozada et al evaluated whether febuxostat could 
alleviate some of the features of the metabolic syndrome as 
well as the renal hemodynamic alterations and afferent arte-
riolopathy induced by a high-fructose diet in rats. They found 
that a high-fructose diet was associated with hyperuricemia, 
hypertension, as well as increased plasma triglycerides and 
insulin. Febuxostat treatment in rats on a high-fructose diet 
resulted in signiﬁ  cant lowering of blood pressure, serum 
urate, triglycerides, and insulin (p  0.05 for all comparisons) 
compared with those without treatment, and it also signiﬁ  -
cantly reduced glomerular pressure, renal vasoconstriction, 
and afferent arteriolar area relative to those without treatment. 
However, febuxostat treatment in rats on a normal diet had 
no signiﬁ  cant effects (Sanchez-Lozada et al 2008a).
Considering the close association between prolonged 
hyperuricemia and renal disease, Sanchez-Lozada et al 
evaluated the effect of febuxostat on progressive renal 
disease in a 5/6 nephrectomy (5/6 Nx) model in Wistar 
rats with and without hyperuricemia induced by the uricase 
inhibitor oxonic acid (OA) (Sanchez-Lozada et al 2008b). 
The 5/6 Nx rats given OA and placebo developed hyper-
uricemia, renal vasoconstriction and glomerular hyperten-
sion in association with further aggravation of afferent 
arteriolopathy compared with those without OA-induced 
hyperuricemia. Febuxostat prevented OA-induced hyper-
uricemia and in 5/6 Nx rats with or without OA-induced 
hyperuricemia it ameliorated proteinuria, preserved renal 
function and prevented glomerular hypertension. Func-
tional improvement was accompanied by preservation of 
afferent arteriolar morphology and reduced tubulointerstitial 
ﬁ  brosis. These results suggested that febuxostat prevented 
renal injury in 5/6 Nx rats with and without coexisting 
hyperuricemia and due to its effect on preserving preglo-
merular vessel morphology, normal glomerular pressure was 
maintained even in the presence of systemic hypertension 
(Sanchez-Lozada et al 2008b).
Using different animal models, the same group of 
researchers also examined the effect of febuxostat on 
hyperuricemia-induced hypertension and renal damage 
(Sanchez-Lozada et al 2008c). They found that in OA-induced 
hyperuricemic rats, febuxostat lowered uric acid and amelio-
rated systemic and glomerular hypertension as well as mesan-
gial matrix expansion and the development of preglomerular 
arteriolar disease as indicated by a reduction of the arteriolar 
area and media-to-lumen ratio. In normal rats, febuxostat 
tended to lower uric acid but had no effect on blood pressure, 
renal hemodynamics, and afferent arteriole morphology. The 
authors suggested that febuxostat merits further evaluation Therapeutics and Clinical Risk Management 2008:4(6) 1212
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for the treatment of hypertension and renal alterations induced 
by hyperuricemia (Sanchez-Lozada et al 2008c).
More recently, Zhao et al (2008) reported the effects of 
chronic XO inhibition by febuxostat or allopurinol on the pro-
gression of chronic heart failure (CHF) induced by left coronary 
artery ligation in rabbits, which have low intrinsic myocardial 
XO activity similar to humans. One day after coronary liga-
tion, rabbits were assigned to early treatment with vehicle or 
febuxostat for 49 days or to delayed-treatment with vehicle 
for 21 days followed by either febuxostat or allopurinol for 28 
days. Treatment with febuxostat initiated shortly after myocar-
dial infarction delayed or prevented the onset of CHF, but XO 
inhibition with either drug initiated after establishment of the 
disease had no cardiac protection effects (Zhao et al 2008).
Pharmacokinetics
After oral administration, about 85% of febuxostat is absorbed 
rapidly with a time (tmax) to reach peak plasma concentrations 
(Cmax) of approximately 1 hour in healthy human subjects 
(Bruce 2006). In a phase I study in which oral febuxostat 
doses of 40, 70, and 120 mg were given to healthy male and 
female adults (n = 154), Cmax values of 1.53, 3.08, and 4.47 
μg/mL occurred at tmax of about 1 hour, with area under the 
plasma concentration-time curve (AUC) values of 4.00, 6.93, 
and 11.31 μg⋅h/mL, respectively. The elimination half-life 
(t1/2) values tended to increase (from 3.8 to 9.1 hours) with 
increasing doses and were longer after multiple doses (6.3 
to 11.9 hours) compared with single doses (Becker et al 
2004a). Escalating dose pharmacokinetic studies of single 
and multiple doses of febuxostat in healthy volunteers have 
shown that Cmax and AUC exhibit an approximately linear 
relation with single doses of 10 to 240 mg and 10 to 120 mg, 
respectively, and nearly dose proportional increases were 
noted for both Cmax and AUC after multiple oral doses with a 
mean apparent total clearance of 10 to 12 L/h and an apparent 
volume of distribution at steady state of 33 to 64 L (Becker 
et al 2004a; Khosravan et al 2006b). The AUC increased more 
than proportionally between the groups receiving 120 and 240 
mg daily suggesting some enterohepatic recirculation (Becker 
et al 2004a; Khosravan et al 2006b) (Table 1).
Febuxostat is highly bound to albumin in blood (∼99%) 
and appears to have a low to medium apparent volume 
of distribution at steady state of approximately 0.7 L/kg 
(Mayer et al 2005). The metabolism of febuxostat occurs 
predominantly in the liver by glucuronidation to produce 
the acyl-glucuronide metabolite (22%–44% of the dose), 
and to a much lesser extent (2%–8%), to produce oxidative 
metabolites, 67M-1, 67M-2, and 67M-4 (Figure 1) by cyto-
chrome P450 enzymes (Khosravan et al 2006b). Approxi-
mately 25% to 45% of the drug was excreted in urine mainly 
as the conjugate with only about 1% to 6% being eliminated 
as the unchanged drug. An additional 2% to 8% of the dose 
was excreted as oxidative metabolites, either unchanged or as 
conjugates. Age and gender did not have statistically or clini-
cally signiﬁ  cant effects on the pharmacokinetics, pharmaco-
dynamics or safety of febuxostat in healthy individuals after 
daily oral dosing with febuxostat at 80 mg for 7 days, which 
suggested that no dose adjustment should be necessary when 
administering febuxostat based on age or gender (Khosravan 
et al 2008b). Patients with gout and/or hyperuricemia treated 
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Figure 1 Chemical structures of (a) febuxostat and metabolites (b) 67M-1, (c) 67M-2, and (d) 67M-4. Adapted with permission from Khosravan R, Grabowski BA, Wu JT, et 
al. 2006b. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin 
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with oral febuxostat at 10 mg daily for 2 weeks, then 20 mg 
daily for a further 4 weeks had similar AUC and Cmax values 
for febuxostat after the last dose as those reported for the same 
dose in healthy male adults (Komoriya et al 2003).
Renal impairment
Although renal clearance may only contribute to a small 
degree to the total systemic clearance of febuxostat, the 
effects of renal impairment on the pharmacokinetics and 
pharmacodynamics of febuxostat have been evaluated 
considering this is of clinical importance as many patients 
with gout may have impaired renal function. A clinical 
study was conducted to examine the pharmacokinetics and 
pharmacodynamics of febuxostat in individuals (n = 15) with 
mild (creatinine clearance [Clcr] 50–80 mL/min) or moderate 
(Clcr 30–50 mL/min) impairment in renal function, compared 
with healthy (Clcr  80 mL/min) participants (Hoshide et al 
2004). The difference in plasma AUC for unchanged febuxo-
stat after single oral doses of 20 mg febuxostat was less than 
2-fold across the groups, indicating that renal impairment 
had little clinical impact on the pharmacokinetic proﬁ  le. 
Changes in plasma urate levels from pre-dose levels were 
not signiﬁ  cant in this study (Hoshide et al 2004).
Another parallel-group, open-label, multiple-dose 
study compared the safety, pharmacokinetics, and 
pharmacodynamics of febuxostat (80 mg/d), administered 
orally for 7 days, in individuals with normal renal function 
(Clcr  80 mL/min/1.73 m; n = 11), or mild (Clcr 50–80 mL/
min/1.73 m; n = 6), moderate (Clcr 30–49 mL/min/1.73 m; 
n = 7), or severe (Clcr 10–29 mL/min/1.73 m; n = 7) renal 
impairment. Mean unbound febuxostat tmax and Cmax values 
in subjects with various degrees of renal impairment were 
similar to those in subjects with normal renal function, 
whereas the mean AUC(24 h) unbound and t1/2z (t1/2 obtained 
by a non-compartment analysis from the terminal slope of 
the concentration-time curve) values tended to increase 
with increasing renal impairment. For the Cmax and AUC(24 h) 
values for the quantiﬁ  able active metabolites 67M-1, 67M-2, 
and 67M-4, with the exception of Cmax for 67M-1, regres-
sion analyses indicated a signiﬁ  cant linear relationship with 
Clcr, suggesting that plasma exposure to the metabolites as 
well as febuxostat was generally increased in proportion to 
the degree of renal impairment. Although plasma exposure 
to febuxostat and its metabolites was generally higher in 
subjects with increasing degrees of renal impairment, the 
percentage reductions in serum urate were comparable, with 
a mean value of 55% to 64% by day 7 irrespective of renal 
function. The 80-mg once-daily dose of febuxostat was safe 
and well tolerated and the investigators concluded that no 
dose adjustment is required based on differences in renal 
function (Mayer et al 2005).
Hepatic impairment
As hepatic metabolism plays an important role in febuxostat 
elimination the effects of hepatic impairment on the pharma-
cokinetics, pharmacodynamics, and safety of febuxostat were 
investigated in a phase I study in individuals with normal 
(n = 11), mildly impaired (Child-Pugh class A; n = 8) or 
moderately impaired (Child-Pugh class B; n = 8) hepatic 
function. Subjects took oral febuxostat 80 mg daily for 
7 days. There were smaller reductions in serum urate in the 
patients with hepatic impairment than in those with normal 
hepatic function but no differences in the pharmacokinetic 
parameters of febuxostat or its metabolites, suggesting the 
dosage may not need to be reduced in patients with mild 
or moderate hepatic dysfunction (Khosravan et al 2006a). 
However, the safety and efﬁ  cacy of febuxostat in patients 
with severe hepatic impairment has not been studied. Liver 
toxicity was not reported in any of the animal studies.
Drug interactions
Febuxostat is highly bound to albumin in blood and is mainly 
metabolized by UDP-glucuronosyltransferase (UGT) 1 and 
2 families and to a lesser extent by cytochrome P450 (CYP) 
enzymes. In vitro studies showed the presence of ibuprofen 
or warfarin did not change the plasma protein binding of 
febuxostat and febuxostat did not inﬂ  uence the plasma protein 
binding of ibuprofen or warfarin, suggesting that febuxostat 
was unlikely to cause a drug-drug interaction by displacement 
of protein binding (Mukoyoshi et al 2008). Examination of 
the inhibitory effect of febuxostat on CYP enzymes suggested 
that it had minimal inhibitory effect on the activities of any 
CYP (Mukoyoshi et al 2008). Based on the in vitro study that 
showed febuxostat had a weak inhibitory effect on CYP2D6, 
but no effect on CYP1A2, CYP2C9, CYP2C19 or CYP3A4, 
Khosravan et al (2005b) examined the effect of multiple 
doses of febuxostat 120 mg daily on the pharmacokinetics 
of desipramine, a substrate for CYP2D6. A small increase 
in total exposure to desipramine was found suggesting that 
CYP2D6-mediated metabolism was mildly inhibited, but 
this was considered clinically insigniﬁ  cant (Khosravan et al 
2005b). The potential interactions between febuxostat and other 
medications which might be concurrently used in patients with 
hyperuricemia and gout have been evaluated in some studies.
Four phase I, two-period, crossover studies were 
performed in healthy male and female subjects to evaluate Therapeutics and Clinical Risk Management 2008:4(6) 1214
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Table 1 Pharmacokinetics of febuxostat
Reference Subjects Dose Results
(Becker et al 2004a; 
Khosravan et al 2006b)
Male and female healthy 
volunteers (n = 142)
Different doses (10, 20, 30, 
40, 50, 70, 90, 120, 160, 180, 
and 240 mg) with 
12 subjects each group 
for 2 weeks
A linear PK and dose-response (% decrease in sUA) 
relationship for febuxostat dosages within the 
10–120 mg range
(Komoriya et al 2004) Patients with gout 
and/or hyperuricemia 
(n = 10)
10 mg daily for 2 weeks 
then 20 mg daily for 
4 weeks
Oxidative metabolites 67M-1, 67M-2, and 67M-4 had 
similar Cmax and tmax as parent drug and 40% of drug 
was excreted in urine as glucuronic acid conjugate 
67-Glu. Data were similar to those reported in 
healthy male adults
(Hoshide et al 2004) Healthy subjects and 
individuals with mild or 
moderate impairment in 
renal function (n = 15)
Single dose of 20 mg The difference in plasma AUC for unchanged 
febuxostat across the groups was less than 2-fold 
indicating that renal impairment had little clinical 
impact on the PK of the drug. Changes in sUA levels 
from pre-dose levels were not signiﬁ  cant
(Mayer et al 2005) Male and female 
subjects with normal 
renal function (n = 11) 
and with mild (n = 6), 
moderate (n = 7) , or 
severe renal impairment 
(n = 7)
80 mg daily dose for 7 days Plasma exposure to febuxostat and its metabolites 
was generally higher in subjects with increasing 
degrees of renal impairment, but the % decrease 
in sUA were comparable regardless of the renal 
function group. No dose adjustment needed for 
febuxostat treatment based on differences in renal 
function
(Khosravan et al 2006a) Subjects with normal 
hepatic function 
(n = 11) and mild 
(n = 8) and moderate 
(n = 8) hepatic 
impairment
80 mg daily dose for 7 days No statistically or clinically signiﬁ  cant differences in 
the plasma PK and PD parameters were observed 
between subjects with mild or moderate hepatic 
impairment and those with normal hepatic function. 
No dose adjustment needed in subjects with mild to 
moderate hepatic impairment
(Khosravan et al 2006c) Male and female healthy 
volunteers, study 1 
(n = 26); study 2 
(n = 24)
In study 1, subjects received 
febuxostat 80 mg once 
daily, indomethacin 50 mg 
twice daily, or both for 
5 days. In study 2, subjects 
received febuxostat 80 mg, 
naproxen 500 mg twice 
daily, or both for 7 days
Febuxostat had no effect on the plasma PK of 
indomethacin and naproxen. Indomethacin had no 
effect on the plasma PK of febuxostat. Although 
naproxen caused an increase in plasma exposure 
to febuxostat, this increase is not expected to be 
clinically signiﬁ  cant
(Khosravan et al 2008a) Male and female healthy 
volunteers (n = 92)
Single 40 mg (n = 24), or 
multiple 80 mg (n = 24), 
or single 120 mg (n = 20) 
in fasting and non-fasting 
conditions, or single 80 mg 
(n = 24) doses alone or 
with antacid
Food caused a decrease in the rate and extent of 
absorption of febuxostat, but this decrease was 
not associated with a clinically signiﬁ  cant change 
in febuxostat PD effect. Despite a decrease in the 
absorption rate of febuxostat, antacid had no effect 
on the extent of febuxostat absorption
(Khosravan et al 
2008b)
Healthy male and female 
subjects (aged 18–40 
years or 65 years) 
(n = 96)
80 mg daily dose for 7 days Age or gender had no clinically signiﬁ  cant effect 
on the PK, PD, or safety of febuxostat
Abbreviations: AUC, area under the plasma concentration-time curve; PD, pharmacodynamic; PK, pharmacokinetic; sUA, serum uric acid.
the effect of food and antacid on the pharmacokinetics 
and/or pharmacodynamics of febuxostat. Food decreased 
rate and extent of absorption of febuxostat, but this decrease 
was not associated with a clinically signiﬁ  cant change in 
the pharmacodynamic effect. With antacid there was a 
decrease in the absorption rate of febuxostat, but no effect 
on the total extent of febuxostat absorption. These ﬁ  ndings 
suggested that febuxostat can be taken with food or antacid 
without a signiﬁ  cant effect on the response (Khosravan 
et al 2008a).Therapeutics and Clinical Risk Management 2008:4(6) 1215
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Grabowski et al (2005) reported that a single dose of 
hydrochlorothiazide 50 mg did not alter the pharmacokinetics 
of febuxostat, but caused a slightly higher serum uric acid 
concentration that was not considered to be clinically 
signiﬁ  cant. Khosravan et al evaluated the potential drug 
interactions between febuxostat and other medication for 
treatment or prevention of acute gout attacks, including 
colchicine, indomethacin and naproxen (Khosravan et al 
2005a, 2006c). Febuxostat had no effect on the plasma phar-
macokinetics of colchicine, indomethacin, and naproxen and 
none of these medications had clinically signiﬁ  cant effects 
on the pharmacokinetics of febuxostat. Therefore, based 
on the plasma pharmacokinetic data in healthy subjects, 
febuxostat can be administered with colchicine, indomethacin 
or naproxen with no dose adjustments.
Safety and efﬁ  cacy in clinical trials
The in vitro and animal studies with febuxostat showed it was 
more potent than allopurinol in reducing serum urate levels 
without any major additional adverse effects (Tomlinson 
2005). A series of clinical trials from phase I to phase III 
have been carried out to evaluate the safety and efﬁ  cacy of 
febuxostat in humans (Table 2).
A phase I, multiple-dose, placebo-controlled, dose-
escalation study was conducted in healthy male and female 
adults in the United States with a majority of Caucasian 
Table 2 Efﬁ  cacy of febuxostat in phase III and long term clinical trials
Reference Patients Study design Treatment Outcomes
(Kamatani et al 
2004)
256 ( Japanese) R, DB, MC, 
8 weeks
FBX 40 mg, ALO 
100 mg BD
82% of patients in the FBX arm achieved 
sUA levels of 6.0, compared with 
69% in the ALO arm
(Becker et al 
2005a) FACT
762 (77% 
Caucasian)
R, DB, MC, 
52 weeks
FBX 80 mg, 120 mg, 
ALO 300 mg
53%, 62%, and 21% of patients in FBX 
80 mg, 120 mg, and ALO 300 mg groups 
achieved sUA 6 mg/dL, respectively 
(p  0.001 for the comparison of each 
febuxostat group with the allopurinol 
group) The overall incidence of gout 
ﬂ  ares was 64% 70%, and 64% for FBX 
80 mg, 120 mg, and ALO 300 mg groups, 
respectively
(Schumacher et al 
2005) APEX
1067 (78% 
Caucasian) 
including 40 
with moderately 
impaired renal 
function
R, PC, 
28 weeks
Placebo, FBX 
80 mg,120 mg, 
240 mg, ALO 
300 mg/100 mg 
(depend on renal 
function)
48%, 65%, 69%, 22%, and 0% of patients 
in FBX 80 mg, 120 mg, 240 mg, ALO 
300/100 mg, and placebo groups 
achieved sUA 6 mg/dL at each of the 
last 3 visits, respectively (p  0.05 for 
all comparison between groups) and 
44%, 45%, 60%, 0%, 0% for subjects with 
moderate renal impairment for each 
groups
(Wortmann et al 
2006) EXCEL
1086 (79% 
Caucasian)
R, OL, LT, 
(an extension 
study of 
2 phase III 
trials above)
FBX 80 mg, 120 mg, 
240 mg, ALO 
300 mg/100 mg 
(depend on renal 
function)
The incidence of gout ﬂ  ares decreased 
gradually from 1.4, 1.72, and 1.49 
fares per year in the 1st year to 0.19, 
0.0, and 0.11 ﬂ  ares per year in the 
3rd year for febuxostat 80 mg, 120 mg, 
and allopurinol 300/100 mg groups, 
respectively
(Schumacher et al 
2006) FOCUS
116 (85% 
Caucasian) 
with 61 subjects 
on continued 
treatment 
with 48 months
OL, LT FBX 40 mg, 
80 mg,120 mg
Across all doses, the proportion of 
subjects with sUA 6.0 mg/dL were 
78%, 76%, 84%, and 90% at year 1, 2, 3, 
and 4, respectively. Overall incidence of 
gout ﬂ  ares requiring treatment declined 
markedly by 2 years and continued over 
4 year of febuxostat treatment. After 
the 1st year of stable dose, subjects, on 
average, had 1 gout ﬂ  are/year
Abbreviations: ALO, allopurinol; DB, double blind; FBX, febuxostat; LT, long term; MC, multicenter; OL, open label; PC, placebo controlled; R, randomized; sUA, serum uric acid.Therapeutics and Clinical Risk Management 2008:4(6) 1216
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subjects (n = 142) (Becker et al 2004a; Khosravan et al 
2006b). Febuxostat was given orally for 2 weeks in daily 
doses in the range of 10 to 240 mg. Febuxostat resulted in 
signiﬁ  cant decreases in serum and urinary urate concentra-
tions and increases in serum and urinary xanthine concentra-
tions. The percentage decreases in serum urate concentrations 
ranged from 27% to 76% (net change: 1.34–3.88 mg/dL), 
which were proportional to dosage for 10 to 120 mg doses 
but higher doses (120 mg) did not appear to have a greater 
effect. Percentage decreases in serum uric acid were 27%, 
35%, 37.5%, 40%, 47%, 50%, 60%, 69%, 70%, 72%, and 
76% for the 10, 20, 30, 40, 50, 70, 90, 120, 160, 180, and 
240 mg doses, respectively. Proportional increases in serum 
xanthine concentrations, decreases in urinary uric acid excre-
tion, and increases in urinary xanthine and hypoxanthine 
excretion were also observed for doses of 10 mg to 120 mg. 
Adverse events were mild or moderate and self-limited, but 
not uncommon. The incidence of adverse events tended to be 
higher with higher doses of febuxostat. No deaths or serious 
adverse events were observed (Khosravan et al 2006b).
Based on the results from the above phase I study, the doses 
for phase II studies were selected and tested in patients with 
gout. A phase II double-blind, placebo-controlled, multicenter 
study included 153 patients, aged 23 to 80 years, with gout 
and baseline serum urate 8.0 mg/dL (Becker et al 2005b). 
Subjects were randomized to febuxostat (40 mg, 80 mg, 
120 mg) or placebo once daily for 28 days with colchicine 
(0.6 mg twice daily) prophylaxis for 14 days prior to and 
14 days after randomization. The subjects achieving the primary 
outcome of serum urate 6.0 mg/dL on day 28, were 0%, 56%, 
76%, and 94% for placebo, 40 mg, 80 mg, and 120 mg dose 
febuxostat groups, respectively (p  0.001 for each treatment 
group vs. placebo). Compared with baseline, decreases in serum 
urate at day 28 were 2%, 37%, 44%, and 59% for placebo, 
40-, 80-, and 120-mg dose groups, respectively (p  0.001 for 
each treatment group vs placebo). Gout ﬂ  ares occurred with 
similar frequency in the placebo (37%) and 40 mg febuxostat 
(35%) groups and with increased frequency in the higher dosage 
febuxostat groups (43% with 80 mg; 55% with 120 mg). During 
colchicine prophylaxis, gout ﬂ  ares occurred less frequently 
(8%–13%). Incidences of treatment-related adverse events 
were similar in the febuxostat and placebo groups (Becker 
et al 2005b).
A long-term, open-label extension of the above 4-week 
double-blind phase II study included 116 patients and 
69 patients continued for at least 2 years (Schumacher et al 
2004; Wortmann et al 2004). Subjects were initially given 
febuxostat 80 mg/day with titration to either 40 or 120 mg 
based on serum urate and adverse events, achieving a stable 
dose after 28 weeks. Colchicine (0.6 mg twice daily) 
prophylaxis was implemented during the initial phase of 
treatment. Most patients (74%–81%) maintained serum 
urate levels of 6.0 mg/dL throughout the study period. Any 
treatment-related adverse events were mild-to-moderate with 
the most common being diarrhea, headache, and abnormal 
liver function test results. No serious adverse event was 
considered to be related to febuxostat. Analysis of a small 
number of patients (n = 9) in this extension study with gouty 
tophi revealed that tophus volume increased in patients with 
serum urate 6.0 mg/dL and decreased in patients with serum 
urate 6.0 mg/dL (Becker et al 2004c). Febuxostat was also 
efﬁ  cacious, safe and well tolerated in a subgroup of allopuri-
nol-intolerant patients included in the trial extension (n = 8) 
(Becker et al 2004b). More recently, the investigators further 
reported the data from 61 subjects with long-term treatment 
with febuxostat for at least 4 years (FOCUS) (Schumacher 
et al 2006). Across all doses, the proportion of subjects 
with serum urate 6.0 mg/dL were 78%, 76%, 84%, and 
90% at year 1, 2, 3, and 4, respectively. The overall inci-
dence of gout ﬂ  ares requiring treatment declined markedly 
by 2 years and continued over 4 years of febuxostat treat-
ment. After the ﬁ  rst year of stable dose, subjects, on average, 
had 1 gout ﬂ  are per year. 26 subjects entered the study with 
a palpable tophus; 20 (77%) of these subjects had no tophus 
detectable at the examinations during the study. The most 
common treatment-related adverse events for all febuxostat 
groups were diarrhea, gastrointestinal motility disorders, 
headache, abnormal liver function tests, and hyperlipidemia. 
This longest clinical study of febuxostat therapy to date 
showed that long-term treatment with febuxostat reducing 
and maintaining serum urate 6.0 mg/dL was accompa-
nied by beneﬁ  cial clinical outcomes, including reduction 
in gout ﬂ  ares and tophus volume (Schumacher et al 2006). 
They also found that 4 years treatment with febuxostat was 
safe, effective, and well tolerated in 6 allopurinol-intolerant 
patients, and 3 subjects with tophi identiﬁ  ed at the time of 
enrollment had disappearance of their tophi by the fourth 
year of febuxostat treatment (Becker et al 2006).
The Febuxostat versus Allopurinol Controlled Trial 
(FACT), a phase III, randomized, double-blind, 52-week, 
multicenter trial, compared the safety and efficacy of 
febuxostat with allopurinol in adult subjects with gout 
(Becker et al 2005a). A total of 762 patients with chronic 
gout and serum urate levels 8.0 mg/dL were randomized 
to receive once-daily doses of either 80 or 120 mg febuxostat 
or 300 mg allopurinol for 52 weeks and 760 received at Therapeutics and Clinical Risk Management 2008:4(6) 1217
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least one dose of the study drug during the study period. 
Naproxen (250 mg twice daily) or colchicine (0.6 mg once 
daily) was provided for gout ﬂ  are prophylaxis during the 
2-week washout period and ﬁ  rst 8 weeks of the study. 
The primary endpoint of serum urate 6.0 mg/dL at all the 
last three measurements at monthly intervals up to 52 weeks 
was reached in 53%, 62%, and 21% of the febuxostat 80 mg 
and 120 mg and allopurinol 300 mg groups, respectively 
(p  0.001 for the comparison of each febuxostat group 
with the allopurinol group). Although the incidence of gout 
ﬂ  ares gradually decreased with continued treatment, the 
overall incidence during weeks 9 through 52 was similar in 
all groups: 64% of patients receiving 80 mg of febuxostat, 
70% of those receiving 120 mg of febuxostat, and 64% of 
those receiving allopurinol. The median reduction in tophus 
area was 83% and 66% in patients receiving 80 mg or 
120 mg of febuxostat and 50% in those receiving allopurinol 
(p  0.05). More patients in the high-dose febuxostat group 
than in the allopurinol group (p = 0.003) or the low-dose 
febuxostat group discontinued the study. The investigators 
concluded that febuxostat 80 mg or 120 mg daily was more 
effective than allopurinol 300 mg daily in reducing serum 
urate (Becker et al 2005a).
Another large phase III study, the APEX study, 
involving 1067 subjects (78% Caucasians) with gout 
and serum urate levels 8.0 mg/dL compared the safety 
and efficacy of febuxostat to allopurinol and placebo 
(Schumacher et al 2005). This study included 40 subjects 
with moderately impaired renal function (serum creatinine 
1.6 to 2.0 mg/dL) and a high dose of febuxostat for safety 
evaluation. Subjects were randomized to receive placebo, 
febuxostat 80 mg, 120 mg, or 240 mg (safety dose) or 
allopurinol once daily in a 1:2:2:1:2 ratio for 28 weeks. 
No dose adjustments based on renal function were made in 
the febuxostat treatment groups, but subjects randomized 
to allopurinol received 300 mg/day if serum creatinine 
was 1.5 mg/dL and 100 mg/day for serum creatinine 
1.6 to 2.0 mg/dL. The primary endpoint of the proportion 
of subjects with serum urate 6.0 mg/dL at each of the 
last 3 visits was achieved in 48%, 65%, 69%, 22%, and 
0% in febuxostat 80 mg, 120 mg, 240 mg, allopurinol 
300/100 mg, and placebo groups, respectively (p  0.05 
for the comparison of each febuxostat group with the 
allopurinol group and placebo group) and 44%, 45%, 60%, 
0%, and 0%, respectively, for subjects with moderate renal 
impairment for each group. After 28 weeks, 76%, 87%, 
94%, 41%, and 1% of patients in febuxostat 80 mg, 120 mg, 
240 mg, allopurinol 300/100 mg, and placebo groups had 
serum urate 6.0 mg/dL (p  0.05 for the comparison of 
each febuxostat group with the allopurinol group and placebo 
group). Adverse events including liver function abnormali-
ties, headache, nausea and vomiting, abdominal pain, and 
dizziness, were similar in incidences across treatment groups. 
There were no increases in adverse events in subjects with 
moderate renal insufﬁ  ciency including those receiving febux-
ostat 240 mg daily. These results suggested that febuxostat 
(80 mg, 120 mg, or 240 mg) demonstrated superior efﬁ  cacy 
compared with placebo and allouprinol (300 or 100 mg) 
in reducing and maintaining serum urate 6.0 mg/dL. 
Febuxostat was generally safe and well tolerated at all doses 
(Schumacher et al 2005).
Clinical beneﬁ  ts of long-term urate-lowering therapy 
with febuxostat have been evaluated in the EXCEL trial, 
which is an extension study of 2 Phase III trials mentioned 
above (FACT and APEX) (Wortmann et al 2006). This 
long-term open-label study was designed to determine if 
subjects treated with febuxostat or allopurinol maintaining 
serum urate 6.0 mg/dL was associated with reduction in 
gout ﬂ  are frequency and tophus resolution. A total of 1086 
subjects completing the above two phase III trials were 
enrolled. At the time of interim analysis, 75% (815/1086) 
of subjects completed 16 months in EXCEL; the dura-
tions of exposure to initial treatment were 492, 428, and 
271 days, respectively, for febuxostat 80 mg, 120 mg, 
and allopurinol 300/100 mg. The incidence of gout ﬂ  ares 
decreased gradually from 1.4, 1.72, 1.49 fares per year in 
the ﬁ  rst year to 0.19, 0.0, and 0.11 ﬂ  ares per year in the 
third year for febuxostat 80 mg, 120 mg, and allopurinol 
300/100 mg groups, respectively. The most common 
febuxostat treatment-related adverse events were abnormal 
liver function tests, headache, hypertension, diarrhea, and 
arthralgia/stiffness, whereas the most common treatment-
related adverse events for allopurinol were abnormal liver 
function tests and rash (Wortmann et al 2006).
The effects of lower doses of febuxostat were evaluated 
in Japanese subjects compared to placebo or allopurinol 
in some studies (Kamatani et al 2003, 2004). A phase II, 
multicenter, double-blind study was conducted to assess the 
efﬁ  cacy and safety of doses of febuxostat in 128 patients 
with gout or hyperuricemia (serum urate levels 8.0 mg/dL). 
Participants were randomized to receive once-daily doses 
of placebo or febuxostat (10 mg, 20mg, or 40 mg; n = 32, 
per group). Patients assigned to the febuxostat groups were 
administered 10 mg febuxostat for the ﬁ  rst 2 weeks, followed 
by 10 mg, 20 mg, or 40 mg for a subsequent 6-week treat-
ment period, while individuals assigned to the placebo group Therapeutics and Clinical Risk Management 2008:4(6) 1218
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received placebo throughout the 8-week trial. Serum urate 
levels of 6.0 mg/dL were achieved in 0%, 22%, 31.5%, and 
41.9% of patients with placebo, 10 mg, 20 mg, and 40 mg 
febuxostat groups, respectively. There was no signiﬁ  cant 
difference in response rate between gout and hyperuricemia 
patients or between urate overproducers or underexcreters. 
Febuxostat was safe and well tolerated at all doses (Kamatani 
et al 2003).
A further phase III study compared the safety and efﬁ  cacy 
of febuxostat with allopurinol in 256 Japanese subjects with 
gout or hyperuricemia with serum urate levels 8.0 mg/dL 
(Kamatani et al 2004). In this randomized, multicenter, 
double-blind study, patients received either febuxostat 
(10 mg once daily) or allopurinol (100 mg once daily) for a 
12-week introductory phase before doses were increased for 
a further 44 days of treatment with febuxostat (40 mg once 
daily) or allopurinol (100 mg twice daily). The decrease in 
serum urate levels after 8 weeks of treatment was signiﬁ  -
cantly (p  0.001) greater in the febuxostat group (40.5%), 
compared with the allopurinol group (33.9%). Furthermore, 
82% of patients in the febuxostat arm achieved serum urate 
levels of 6.0, compared with 69% in the allopurinol arm 
(p  0.05). Adverse reactions were reported in 11% of 
patients in the allopurinol group and 8.6% in the febuxostat 
group. The majority of adverse events were transient and 
mild in severity (Kamatani et al 2004).
Summary
Febuxostat has been shown to be safe and effective in 
lowering serum urate according to the available clinical 
data. Doses of 80 mg of febuxostat are more effective in 
lowering serum urate than doses of 300 mg of allopurinol. 
Febuxostat has shown to be well tolerated in long term 
treatment in patients experiencing hypersensitity/intolerance 
to allopurinol.
Dose adjustment does not seem to be necessary in patients 
with mild to moderate renal/liver insufﬁ  ciency or advanced 
age according to data from these particular groups of subjects. 
The most common adverse reactions reported were abnormal 
liver function tests, headache, and gastrointestinal symptoms, 
which were usually mild and transient. Hepatotoxicity was 
not a feature in the animal studies, but whether it becomes 
a limitation in the clinical use of febuxostat needs to be 
determined in further studies. As with other urate-lowering 
therapies, the rapid decrease in serum urate associated with 
initiation of treatment with febuxostat caused a number of 
patients to experience acute gout ﬂ  ares. This appeared to be 
more frequent with the more potent serum urate-lowering 
effects of higher doses of febuxostat, but this increased 
incidence of gout attacks tended to decline with ongoing 
treatment and could be attenuated with concomitant prophy-
laxis during the initiation of febuxostat therapy. In February 
2008, 80 mg and 120 mg of febuxostat ﬁ  lm-coated tablets 
(Adenuric®) were granted marketing authorization by the 
European Commission for the treatment of chronic hyper-
uricemia in conditions in which urate deposition has already 
occurred (including a history or presence of tophus and/or 
gouty arthritis), which is the ﬁ  rst major treatment alternative 
for gout in more than 40 years (CHMP 2008; Ipsen 2008). 
A concern on potential serious cardiovascular adverse events 
was noted in the European Commission statement, but this 
was not apparent in the published clinical trial reports.
In summary, febuxostat is a promising urate-lowering 
therapy as an alternative to allopurinol for the treatment of 
hyperuricemia and gout, although further observation on 
post-marketing safety and efﬁ  cacy of long term treatment 
with febuxostat in patients with gout or hyperuricemia and 
with other complications is required.
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